-
MULTICENTER PHASE II NEOADJUVANT AND ADJUVANT STUDY OF ALECTINIB ENTRECTINIB OR VEMURAFENIB PLUS COBIMETINIB IN PATIENTS WITH STAGES I-III NON-SMALL CELL LUNG CANCER WITH ALK ROS1 NTRK OR BRAF V600E MOLECULAR ALTERATIONS
The purpose of the trial is to determine the efficacy and safety of drugs in patients with untreated non-small cell lung cancer (NSCLC) tumors. In ... -
A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations
The purpose of the study is to compare standard chemotherapy to therapy with CPX-351 and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia ... -
Site for EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response
The purpose of the study is to determine the safety and tolerability of pre-operative therapy with 12 weeks of taxane, trastuzumab (or FDA approved biosimilar ... -
A MULTI-CENTER OPEN LABEL PHASE 1/2 STUDY OF CYT-0851 AN ORAL RAD51 INHIBITOR IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES AND ADVANCED SOLID TUMORS
The purpose of the study to determine the safety of CYT-0851 in patients with relapsed/refractory B-Cell malignancies and advanced solid tumors. The study drug ... -
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors
The purpose of the study is to determine the overall response rates as well as safety and tolerability of olaparib in subjects with recurrent/progressive ... -
A Phase I study of Anetumab Ravtansine in Combination with either Anti-PD-1 Antibody or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
The purpose of the study is to determine the side effects and best dose of anetumab ravtansine when given together with nivolumab, ipilimumab and gemcitabine ... -
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2)
The purpose of the study is to evaluate the biological activity of systemic therapies in people with Neurofibromatosis type 2 (NF2) related tumors. Tumor types ... -
A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
The purpose of the study is to determine if M3814 in combination with radiation therapy and avelumab is safe and tolerable in patients with advanced ... -
A Phase 1 First-in Human Multi-Center Open Label Dose-Escalation Study to Determine the Safety Tolerability Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors (AbbVie M19-345)
The purpose of the study is to look at safety and efficacy of study drug ABBV-151 alone and in combination with study drug ABBV-181. We ... -
A randomized Phase I/II trial of fulvestrant and abemaciclib in combination with copanlisib (FAC) versus fulvestrant and abemaciclib alone (FA) for endocrine-resistant hormone receptor positive HER2 negative metastatic breast cancer (FAC vs FA)
The purpose of the study is to determine the effects (good and bad) of adding copanlisib to the usual therapy of fulvestrant and abemaciclib in ...